Related Experiment Video

Updated: Apr 28, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.2K

Nucleophosmin1 associated with drug resistance and recurrence of bladder cancer

Huihui Hu1, Qian Meng, Ting Lei

  • 1Department of Clinical Laboratory, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China, huhuihui1101@163.com.

Clinical and Experimental Medicine
|June 14, 2014
PubMed

Insights

Nucleophosmin1 expression is linked to drug resistance and recurrence in bladder cancer. Lower nucleophosmin1 levels in tissues correlate with later recurrence, suggesting its role in treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Drug resistance and cancer recurrence are significant challenges in bladder cancer chemotherapy.
  • Previous research identified nucleophosmin1 as differentially expressed in bladder cancer cell lines.

Purpose of the Study:

  • To investigate the relationship between nucleophosmin1 expression, drug resistance, and recurrence in bladder cancer.
  • To evaluate nucleophosmin1 as a potential biomarker for clinical drug treatment and recurrence prediction.

Main Methods:

  • Utilized normal bladder epithelia (SV-HUC-1) and bladder cancer cell lines (PUMC-91) with varying adriamycin resistance.
  • Analyzed bladder cancer tissue samples stratified by recurrence interval (<6 months vs. >2 years).
  • Employed Western blotting and immunohistochemistry to detect nucleophosmin1 protein expression.

Main Results:

  • Nucleophosmin1 showed differential expression across cell lines with increasing adriamycin resistance (p < 0.05).
  • Significantly lower nucleophosmin1 expression was observed in bladder cancer tissues with later recurrence (>2 years) compared to early recurrence (<6 months) (p = 0.035).
  • Nucleophosmin1 expression was independently associated with both drug resistance and recurrence frequency.

Conclusions:

  • Nucleophosmin1 plays a key regulatory role in both drug-resistant bladder cancer and bladder cancer recurrence models.
  • Nucleophosmin1 expression levels may offer valuable prognostic information for bladder cancer patients, particularly concerning drug treatment efficacy and predicting recurrence.

More Related Videos

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

6.9K
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

9.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K